GRIFOLS SA INH. A EO-,25/ ES0171996087 /
| 11/11/2024 9:43:11 AM | Chg. +0.175 | Volume | Bid9:52:00 AM | Ask9:52:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 11.040EUR | +1.61% | 70 Turnover: 790.650 |
11.050Bid Size: 2,714 | 11.060Ask Size: 2,714 | 9.36 bill.EUR | - | 121.89 |
GlobeNewswire
7/29
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strength...
GlobeNewswire
7/1
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
GlobeNewswire
6/18
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
GlobeNewswire
6/17
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immu...
GlobeNewswire
4/18
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at ...
GlobeNewswire
4/4
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Scree...
GlobeNewswire
11/15/2023
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous ...
